#NEWS: Today, we announced data presentations at EADV and Fall Clinical. Read our release for full details: arcutis.com/arcutis-presents… #ClinicalDermatology #MeaningfulInnovation

We’re proud to share that Arcutis’ advanced targeted topical treatment for #eczema has earned a 2026 Marie Claire Beauty Award. ✨ Thank you, @marieclaire, for this meaningful recognition. Read the release: arcutis.com/arcutis-zoryve-r… #MarieClaire #BeautyAwards #Dermatology

We're thrilled to announce our partnership with world champion gymnast Simone Biles as part of the Skin to Believe In Campaign! Learn more: arcutis.com/simone-biles-par… #MeaningfulInnovation #ClinicalDermatology #SeborrheicDermatitis #AtopicDermatitis

We’re excited to be in NYC at the Morgan Stanley 24th Annual Global Healthcare Conference, where Arcutis President and CEO, Frank Watanabe, CMO, Patrick Burnett, MD, PhD, FAAD and CFO, Latha Vairavan, will be hosting a fireside chat. Details below. #ClinicalDermatology

#NEWS: Today, we announced #Q2 2026 financial results. Read our release for full details and business updates: investors.arcutis.com/news-r…

#NEWS: We're pleased to welcome Chris Peetz to our Board of Directors — a proven leader in scaling biopharmaceutical organizations and building commercial franchises. Read more: arcutis.com/arcutis-expands-…

#NEWS: The FDA has accepted our sNDA to expand the indication of our advanced targeted topical for the treatment of #AtopicDermatitis to infants down to 3 months. Learn more: arcutis.com/fda-accepts-supp… #ClinicalDermatology

#NEWS: Today we announced the launch of our new virtual health platform to expand access to our advanced topical treatments for chronic inflammatory skin diseases. Learn more: arcutis.com/arcutis-launches… #ClinicalDermatology #MeaningfulInnovation

#NEWS: Our topical cream 0.3% is now the first once-daily, non-steroidal therapy approved by the FDA for children with plaque psoriasis as young as 2 years of age. Read more: arcutis.com/fda-approves-arc… #CompanyMilestone #FDAapproval #Innovation #Psoriasis #PediatricDermatology

Tomorrow, Arcutis President and CEO Frank Watanabe and Chief Financial Officer Latha Vairavan will be participating in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. More details below. #ClinicalDermatology

#NEWS: Today we announced the publication of age-specific expert recommendations to help improve the recognition, diagnosis and management of genital #psoriasis across pediatric, adult, and older populations. Read more: arcutis.com/new-expert-conse… #ClinicalDermatology

#NEWS: Today, we announced #Q1 2026 financial results and provided a business update. Read our release for full details: investors.arcutis.com/news-r… $ARQT

#NEWS: Today we submitted an application to the @US_FDA to expand the indication for our topical treatment for #AtopicDermatitis to include infants ages 3-24 months. Learn more: arcutis.com/arcutis-submits-…

#NEWS: Today we announced that our topical cream has received a strong recommendation in @AADskin's first-ever guidelines for children and adolescents with mild to moderate #AtopicDermatitis. Learn more: arcutis.com/arcutis-zoryve-r… #ClinicalDermatology

Today, Arcutis President and CEO Frank Watanabe and Chief Financial Officer Latha Vairavan will be participating in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference. More details below. #ClinicalDermatology

Advanced targeted topicals are expanding options for people with chronic inflammatory #SkinDiseases. Arcutis President and CEO Frank Watanabe and CMO Patrick Burnett explain how these therapies may help address a long-sought balance between treatment goals. Watch to learn more.

#NEWS: Today we announced the presentation of new, late-breaking data from our INTEGUMENT-INFANT trial in #AtopicDermatitis at @AADskin’s 2026 Annual Meeting. Learn more: arcutis.com/arcutis-presents… #AAD2026 #ClinicalDermatology #ArcutisAtAAD

#ICYMI: We’re back at @AADskin’s 2026 Annual Meeting and will be sharing data from our investigational studies in #AtopicDermatitis, #SeborrheicDermatitis, and #Psoriasis. Come see us at booth #540. Learn more: arcutis.com/arcutis-to-prese… #AAD2026 #ClinicalDermatology #ArcutisAtAAD

Our 2025 annual report and shareholder letter are now available. Our achievements in 2025 strengthened Arcutis’ position as a leading medical dermatology company. Building on this momentum, we'll continue to grow, expand, and build in 2026. Read more: investors.arcutis.com/financ…

#NEWS: We’re excited to be back at @AADskin’s 2026 Annual Meeting and look forward to sharing data from our studies in #AtopicDermatitis, #SeborrheicDermatitis, and #Psoriasis. Learn more: arcutis.com/arcutis-to-prese… #AAD2026 #ClinicalDermatology #ArcutisAtAAD